148 related articles for article (PubMed ID: 18201152)
1. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments.
Benesch M; Urban C
Expert Opin Pharmacother; 2008 Feb; 9(2):301-9. PubMed ID: 18201152
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.
Kripp M; Hofheinz RD
Int J Nanomedicine; 2008; 3(4):397-401. PubMed ID: 19337408
[TBL] [Abstract][Full Text] [Related]
3. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.
Rueda Domínguez A; Olmos Hidalgo D; Viciana Garrido R; Torres Sánchez E
Clin Transl Oncol; 2005 Jul; 7(6):232-8. PubMed ID: 16131445
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Brion A; Legrand F; Larosa F; Schillinger F; Garnache-Ottou F; Helias P; Fontan J; Heczko M; Delaby P; Daguindau E; Vuillier J; Chauchet A; Deconinck E
Invest New Drugs; 2012 Aug; 30(4):1697-702. PubMed ID: 21229289
[TBL] [Abstract][Full Text] [Related]
5. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.
Sancho JM; Ribera JM; Romero MJ; Martín-Reina V; Giraldo P; Ruiz E
Haematologica; 2006 Mar; 91(3):ECR02. PubMed ID: 16533729
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
Phuphanich S; Maria B; Braeckman R; Chamberlain M
J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075
[TBL] [Abstract][Full Text] [Related]
7. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
Sancho JM; Deben G; Parker A; Piñana JL; Bolam S; Sánchez-García E; Giménez E; Pascual T; Fernández-Abellán P; Palomera L; Ribera JM
Int J Hematol; 2007 Jul; 86(1):33-6. PubMed ID: 17675264
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma.
Spina M; Chimienti E; Martellotta F; Vaccher E; Berretta M; Zanet E; Lleshi A; Canzonieri V; Bulian P; Tirelli U
Cancer; 2010 Mar; 116(6):1495-501. PubMed ID: 20108270
[TBL] [Abstract][Full Text] [Related]
9. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.
Garcia-Marco JA; Panizo C; Garcia ES; Deben G; Alvarez-Larran A; Barca EG; Sancho JM; Penarrubia MJ; Garcia-Cerecedo T; Garcia Vela JA
Cancer; 2009 May; 115(9):1892-8. PubMed ID: 19235254
[TBL] [Abstract][Full Text] [Related]
12. Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine.
Prescrire Int; 2006 Feb; 15(81):11-2. PubMed ID: 16548098
[TBL] [Abstract][Full Text] [Related]
13. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
16. Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report.
Gaviani P; Silvani A; Corsini E; Erbetta A; Salmaggi A
Neurol Sci; 2009 Jun; 30(3):251-4. PubMed ID: 19259616
[TBL] [Abstract][Full Text] [Related]
17. New liposomal cytarabine formulation in CSF.
Casado P; Torreira C; Oujo E; Esteban P; Albo C; Diaz R; Andrade MA
Clin Lab; 2010; 56(1-2):69-70. PubMed ID: 20380362
[No Abstract] [Full Text] [Related]
18. Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine.
Bohn JP; Reinstadler V; Pall G; Stockhammer G; Steurer M; Oberacher H; Wolf D
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):845-851. PubMed ID: 31435852
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis.
Jahn F; Jordan K; Behlendorf T; Globig C; Schmoll HJ; Müller-Tidow C; Jordan B
Oncology; 2015; 89(3):137-42. PubMed ID: 25791073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
